REMARKS

Restriction Requirement

Applicants hereby elect Group II, claims 4 and 17 drawn to a kit comprising isolated nucleic acid molecules and isolated nucleic acid molecules, without traverse.

Status of the claims

Claims 1-20 are pending and are subject to restriction. Claims 4 and 17 are elected. Claims 1-3, 5-16 and 18-20 are canceled. New claims 21-23 are added. No new matter is added in these new claims.

Claim amendments

New claims 21-23 are original claims 1-3 that were amended to depend indirectly from independent claim 17. These claims are drawn to a method of genotyping human multidrug resistance gene (MDR1) single nucleotide polymorphism C3435T. This method comprises preparing DNA samples from an individual. The DNA is then amplified with a primer pair comprising wild typespecific primer (SEQ ID No.1) or a mutant-specific primer (SEQ ID

No. 2) and a common reverse primer (SEQ ID No. 3) as shown in

Table 1. The products of the DNA amplification are then identified

where the presence of products amplified by the mutant specific

primer (SEQ ID No. 2) and the reverse primer (SEQ ID No. 3)

indicate that the individual has the genotype C3435T. Applicants

submit that no new matter is added in new claims 21-23 and that

new claims 21-23 properly belong to Group II.

Applicants believe that no fees are due, however, should

this be in error, please debit Deposit Account No. 07-1185 on which

the undersigned is allowed to draw.

Respectfully submitted,

Date:<u> *R</u></u>*

ADLER & ASSOCIATES 8011 Candle Lane

Houston, Texas 77071

Tel: (713) 270-5391 Fax: (713) 270-5361

BADLER1@houston.rr.com

Benjamin Aaron Adler, J.D., Ph.D.

Registration No. 35,423 Counsel for Applicant

5